Rockwell appoints Richard Zager to scientific advisory board

WIXOM, Mich.—Specialty pharma company Rockwell Medical Technologies Inc. said June 10 that it has added Dr. Richard Zager, an expert in acute renal injury and renal failure, to its scientific advisory board.

Rockwell’s scientific advisory board advises the company on clinical development and market preparation for its proprietary iron-maintenance product SFP, currently in phase 2b clinical trials, according to Rockwell.

Rockwell's scientific advisory board consists of experts in the fields of renal anemia, iron therapy, nephrology and U.S. Food and Drug Administration regulatory approval.

Zager is the director of Nephrology at Seattle-based FredHutchinsonCancerResearchCenter. He is a board certified internist and nephrologist with 35 years of clinical experience. In addition, he has supervised an U.S. National Institutes of Health-funded basic research laboratory for the past 30 years.

"We're delighted to have Dr. Zager join our team,” Robert L. Chioini, chairman, CEO and president of Rockwell, said in a statement. "His expertise in iron mediated biochemical and cellular effects will be invaluable as Rockwell undertakes clinical studies exploring the potential advantages of SFP over the conventional polymeric iron complexes used for intravenous administration."